Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis

Abstract Objective To determine the annual rate of tuberculosis development after a positive tuberculin skin test (TST) or interferon-gamma release assay result (IGRA), or both, among untreated populations with characteristics believed to increase the risk of tuberculosis (at risk populations). Design Systematic review and meta-analysis. Data sources Embase, Medline, and Cochrane Controlled Register of Trials from 1 January 1990 to 17 May 2019, for studies in humans published in English or French. Reference lists were reviewed. Eligibility criteria and data analysis Retrospective or prospective cohorts and randomised trials that included at least 10 untreated participants who tested positive to tuberculosis antigens (contained in TST or IGRA, or both) followed for at least 12 months. Following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and meta-analyses of observational studies in epidemiology (MOOSE) guidelines, two reviewers independently extracted study data and assessed quality using a modified quality assessment of diagnostic accuracy studies (QUADAS-2) tool. Data were pooled using random effects generalised linear mixed models. Main outcome measures The primary outcome was tuberculosis incidence per 1000 person years among untreated participants who tested positive (TST or IGRA, or both) in different at risk subgroups. Secondary outcomes were the cumulative incidence of tuberculosis and incidence rate ratios among participants with a positive test result for latent tuberculosis infection compared with those with a negative test result in at risk subgroups. Results 122 of 5166 identified studies were included. In three general population studies, the incidence of tuberculosis among 33 811 participants with a TST induration of ≥10 mm was 0.3 (95% confidence interval 0.1 to 1.1) per 1000 person years. Among 116 197 positive test results for latent tuberculosis infection in 19 different at risk populations, incidence rates were consistently higher than those in the general population. Among all types of tuberculosis contacts, the incidence of tuberculosis was 17.0 (95% confidence interval 12.9 to 22.4) per 1000 person years for participants with a positive IGRA result and 8.4 (5.6 to 12.6) per 1000 person years for participants with a positive TST result of ≥5 mm. Among people living with HIV, the incidence of tuberculosis was 16.9 (10.5 to 27.3) for participants with a positive IGRA result and 27.1 (15.0 to 49.0) for participants with a positive TST result of ≥5 mm. Rates were also high for immigrants, people with silicosis or requiring dialysis, transplant recipients, and prisoners. Incidence rate ratios among test positive versus test negative participants were significantly greater than 1.0 in almost all risk groups, for all tests. Conclusions The incidence of tuberculosis is substantial in numerous at risk populations after a positive TST or IGRA result. The information from this review should help inform clinical decisions to test and treat for latent tuberculosis infection. Study registration PROSPERO CRD42019136608.

[1]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[2]  D. Dowdy,et al.  Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries , 2019, PLoS medicine.

[3]  A. Getahun,et al.  Assessing the Impact of Isoniazid Preventive Therapy (IPT) on Tuberculosis Incidence and Predictors of Tuberculosis among Adult Patients Enrolled on ART in Nekemte Town, Western Ethiopia: A Retrospective Cohort Study , 2019, Interdisciplinary perspectives on infectious diseases.

[4]  A. Levin,et al.  Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  M. Egger,et al.  Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations , 2018, BMC Medical Research Methodology.

[6]  S. Bosnic-Anticevich,et al.  Physicians' perspectives on communication and decision making in clinical encounters for treatment of latent tuberculosis infection , 2018, ERJ Open Research.

[7]  A. Tsertsvadze,et al.  Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis , 2017, BMC Infectious Diseases.

[8]  T. Ball,et al.  Latent tuberculosis infection: An overview. , 2017, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[9]  I. Abubakar,et al.  Diagnosis and Management of Latent Tuberculosis Infection. , 2015, Cold Spring Harbor perspectives in medicine.

[10]  R. Chaisson,et al.  Latent Mycobacterium tuberculosis infection. , 2015, The New England journal of medicine.

[11]  Lyle C Gurrin,et al.  Meta-analysis of incidence rate data in the presence of zero events , 2015, BMC Medical Research Methodology.

[12]  A. Date,et al.  Use of Isoniazid Preventive Therapy for Tuberculosis Prophylaxis Among People Living With HIV/AIDS: A Review of the Literature , 2015, Journal of acquired immune deficiency syndromes.

[13]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[14]  E. Hershfield,et al.  Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection , 2013, Pediatric Clinical Practice Guidelines & Policies.

[15]  M. Pai,et al.  Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection , 2014, Clinical Microbiology Reviews.

[16]  C. Dye,et al.  Prospects for tuberculosis elimination. , 2013, Annual review of public health.

[17]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[18]  Gordon H Guyatt,et al.  GRADE guidelines: 5. Rating the quality of evidence--publication bias. , 2011, Journal of clinical epidemiology.

[19]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[20]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[21]  R. Andrade,et al.  Hepatic safety of antibiotics used in primary care , 2011, The Journal of antimicrobial chemotherapy.

[22]  Aman Verma,et al.  The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices , 2011, PLoS medicine.

[23]  Masahiro Narita,et al.  Revisiting rates of reactivation tuberculosis: a population-based approach. , 2010, American journal of respiratory and critical care medicine.

[24]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[25]  R. Atun,et al.  Health-system strengthening and tuberculosis control , 2010, The Lancet.

[26]  R. Chaisson,et al.  Recurrent tuberculosis: relapse, reinfection, and HIV. , 2010, The Journal of infectious diseases.

[27]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[28]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[29]  M. Murray,et al.  Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies , 2008, PLoS medicine.

[30]  Theo Stijnen,et al.  The binomial distribution of meta-analysis was preferred to model within-study variability. , 2008, Journal of clinical epidemiology.

[31]  F. van Leth,et al.  Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. , 2008, Bulletin of the World Health Organization.

[32]  M. Pai,et al.  Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research , 2007, Annals of Internal Medicine.

[33]  G. Hussey,et al.  Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[34]  R. Horsburgh,et al.  Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.

[35]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[36]  S D Walter,et al.  A comparison of methods to detect publication bias in meta‐analysis , 2001, Statistics in medicine.

[37]  D. Haas,et al.  The case against anergy testing as a routine adjunct to tuberculin skin testing. , 2000, JAMA.

[38]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[39]  J. Fitzgerald,et al.  Risk of tuberculosis in dialysis patients: a population-based study. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[40]  P. Garner,et al.  Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials , 1998, BMJ.